Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

760254

544644

CORONA

img img img img
No Data Available

Corona Remedies Ltd Share Price Update

As of the latest trading session, Corona Remedies Ltd share price is currently at ₹ 1479.2, which is up by ₹ 12.79 from its previous closing. Today, the stock has fluctuated between ₹ 1447.10 and ₹ 1486.00. Over the past year, Corona Remedies Ltd has achieved a return of [-] %. In the last month alone, the return has been 6.79 %. Read More...

Corona Remedies Ltd performance

Today’s low

Today’s high

₹ 1447.10 ₹ 1486.00
₹ 1479.20

52 week low

52 week high

₹ 1336.60 ₹ 1541.00
₹ 1479.20

Open Price

₹ 1462.50

Prev. Close

₹ 1466.40

Volume (Shares)

27135.00

Total traded value

₹ 401.38

Upper Circuit

₹ 1759.60

Lower Circuit

₹ 1173.20

info

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months 0.00% Over 1 Year 0.00%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Corona Remedies Ltd fundamentals


  • Market cap (Cr)

    9,046.80

  • P/E Ratio (TTM)

    60.72

  • Beta

    0.92

  • Book Value / share

    99.03

  • Return on equity

    27.45%

  • EPS (TTM)

    24.46

  • Dividend yield

    0.49%

  • Net profit/quarter (Cr)

    52.15

info icon alternate text
  • Market cap (Cr)

    9,049.60

  • P/E Ratio (TTM)

    60.72

  • Beta

    1.14

  • Book Value / share

    99.03

  • Return on equity

    27.45%

  • EPS (TTM)

    24.46

  • Dividend yield

    0.49%

  • Net profit/quarter (Cr)

    52.15

info icon alternate text

Corona Remedies Ltd Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 361.13
Operating Expense 293.79
Net Profit 52.15
Net Profit Margin (%) 14.44
Earnings Per Share (EPS) 8.53
EBITDA 80.74
Effective Tax Rate (%) 25.08
Particulars JUN 2025 (Values in Cr)
Revenue 346.54
Operating Expense 287.67
Net Profit 46.40
Net Profit Margin (%) 13.38
Earnings Per Share (EPS) 7.59
EBITDA 71.80
Effective Tax Rate (%) 23.79
Particulars SEP 2024 (Values in Cr)
Revenue 313.87
Operating Expense 258.97
Net Profit 42.98
Net Profit Margin (%) 13.69
Earnings Per Share (EPS) 7.03
EBITDA 69.28
Effective Tax Rate (%) 25.06
Particulars JUN 2024 (Values in Cr)
Revenue 291.17
Operating Expense 0.00
Net Profit 29.95
Net Profit Margin (%) 10.28
Earnings Per Share (EPS) 4.90
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 1196.42
Operating Expense 1004.20
Net Profit 149.05
Net Profit Margin (%) 12.45
Earnings Per Share (EPS) 24.37
EBITDA 245.91
Effective Tax Rate (%) 24.77
Particulars MAR 2025 (Values in Cr)
Book Value / Share 99.14
ROE % 27.50
ROCE % 29.82
Total Debt to Total Equity 0.23
EBITDA Margin 20.59
Particulars MAR 2024 (Values in Cr)
Book Value / Share 78.55
ROE % 20.36
ROCE % 23.46
Total Debt to Total Equity 0.21
EBITDA Margin 15.89
Particulars MAR 2023 (Values in Cr)
Book Value / Share 66.80
ROE % 20.79
ROCE % 24.94
Total Debt to Total Equity 0.07
EBITDA Margin 15.30
Particulars MAR 2025 (Values in Cr)
Book Value / Share 99.04
ROE % 27.45
ROCE % 29.78
Total Debt to Total Equity 0.23
EBITDA Margin 20.55
Particulars MAR 2024 (Values in Cr)
Book Value / Share 78.51
ROE % 20.38
ROCE % 23.47
Total Debt to Total Equity 0.21
EBITDA Margin 15.89
Particulars MAR 2023 (Values in Cr)
Book Value / Share 66.70
ROE % 23.24
ROCE % 27.29
Total Debt to Total Equity 0.08
EBITDA Margin 15.27
Particulars MAR 2022 (Values in Cr)
Book Value / Share 62.86
ROE % -0.18
ROCE % 0.95
Total Debt to Total Equity 0.13
EBITDA Margin 3.93
Particulars MAR 2021 (Values in Cr)
Book Value / Share 727.91
ROE % 23.09
ROCE % 25.14
Total Debt to Total Equity 0.16
EBITDA Margin 19.15
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 69.27
Total Assets 929.86
Total Liabilities 929.86
Total Equity 606.34
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 16.07
Return on Capital (%) 22.34
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 69.90
Total Assets 830.57
Total Liabilities 830.57
Total Equity 480.40
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 10.89
Return on Capital (%) 14.73
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 76.69
Total Assets 595.02
Total Liabilities 595.02
Total Equity 408.52
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 14.27
Return on Capital (%) 20.67
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 69.27
Total Assets 929.24
Total Liabilities 929.24
Total Equity 605.72
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 16.03
Return on Capital (%) 22.3
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 69.90
Total Assets 830.34
Total Liabilities 830.34
Total Equity 480.17
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 10.89
Return on Capital (%) 14.73
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 76.69
Total Assets 594.79
Total Liabilities 594.79
Total Equity 408.29
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 14.24
Return on Capital (%) 20.63
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 100.97
Total Assets 511.36
Total Liabilities 511.36
Total Equity 320.90
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) -0.07
Return on Capital (%) -0.11
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 39.55
Total Assets 396.31
Total Liabilities 396.31
Total Equity 269.15
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 14.98
Return on Capital (%) 19.01
Particulars MAR 2025 (Values in Cr)
Net Income 198.53
Cash from Operations 233.77
Cash from Investing -83.84
Cash from Financing -106.58
Net change in Cash 0.06
Free Cash Flow 325.41
Particulars MAR 2024 (Values in Cr)
Net Income 118.48
Cash from Operations 174.66
Cash from Investing -266.64
Cash from Financing 98.54
Net change in Cash -11.34
Free Cash Flow 461.00
Particulars MAR 2023 (Values in Cr)
Net Income 110.88
Cash from Operations 128.52
Cash from Investing -50.24
Cash from Financing -44.74
Net change in Cash 7.70
Free Cash Flow 223.27
Particulars MAR 2025 (Values in Cr)
Net Income 198.14
Cash from Operations 233.77
Cash from Investing -83.83
Cash from Financing -106.58
Net change in Cash 0.06
Free Cash Flow 325.42
Particulars MAR 2024 (Values in Cr)
Net Income 118.47
Cash from Operations 174.66
Cash from Investing -266.64
Cash from Financing 98.54
Net change in Cash -11.34
Free Cash Flow 461.00
Particulars MAR 2023 (Values in Cr)
Net Income 110.66
Cash from Operations 128.52
Cash from Investing -50.24
Cash from Financing -44.74
Net change in Cash 7.70
Free Cash Flow 223.28
Particulars MAR 2022 (Values in Cr)
Net Income -0.79
Cash from Operations 99.20
Cash from Investing -65.77
Cash from Financing -29.85
Net change in Cash 2.03
Free Cash Flow 133.20
Particulars MAR 2020 (Values in Cr)
Net Income 78.34
Cash from Operations 60.19
Cash from Investing -50.24
Cash from Financing 32.40
Net change in Cash 22.92
Free Cash Flow 60.19
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.58 13.52 1.43 211.35 23.12 / 53.83
BLISS GVS PHARMA LTD 176.85 17.07 1.65 1870.88 105.05 / 195.85
CIPLA LTD 1323.95 22.49 3.24 106946.12 1283.00 / 1672.20
FERMENTA BIOTECH LIMITED 322.30 8.47 2.42 948.56 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.58 22.42 3.84 211.35 23.12 / 53.83
AMRUTAJAN HEALTH LTD 587.90 29.98 4.96 1699.66 548.05 / 789.95
ASTRAZENECA PHARMA IND LT 8536.35 92.31 26.70 21340.88 6501.60 / 10653.05
BLISS GVS PHARMA LTD 176.85 23.87 1.69 1870.88 105.05 / 195.85

Corona Remedies Ltd shareholding pattern

Holding

22.4%
68.99%
1.83%
6.76%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

Corona Remedies Ltd Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1479.20 0.87 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 1454.00
  • 26 Days 1425.00
  • 10 Days 1445.50
  • 50 Days 1420.10
  • 12 Days 1443.50
  • 100 Days 1420.10
  • 20 Days 1433.60
  • 200 Days 1420.10
1448.67 PIVOT

First Support

1418.73

First Resistance

1496.33

Second Support

1371.07

Second Resistance

1526.27

Third Support

1341.13

Third Resistance

1573.93

RSI

56.07

ADX

36.38

MACD

18.42

Williams % R

-34.90

Commodity Channel Index (CCI)

70.47

Date

2026-01-30

Week

27412.00

Same Day

14008.00

Month

42942.00

1 Year

0.93

3 Year

0.92

Over 1 Month

6.79%

down

Over 1 Year

0.00%

down

Over 3 Months

2.83%

down

Over 3 Years

0.00%

down

Over 6 Months

0.00%

down

Over 5 Years

0.00%

down

Corona Remedies Ltd Corporate Actions

Top Gainers

Corona Remedies Ltd Share Price

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'. A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.

The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat). The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.

In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005. The production of first manufacturing plant was commissioned at Solan, Himachal Pradesh in 2007. The Company launched Gynaecology division in 2008; further launched Cardioloy division in 2013; launched Cardiovascular disease (CVD) and Solis division in 2016. Later, the production at Ahmedabad Plant commissioned in Gujarat in 2021. Radiance and Solaris Divisions launched in 2022; followed by Urology division in 2023.

The Company acquired the Myoril brand from Sanofi Healthcare India Private Limited in strengthening the pain management portfolio in 2024.

Company issued 6,174,051 equity shares of face value of Rs 10, by raising Rs 655.37 crore through offer for sale on December 10, 2025.

In addition to urology, Company focus on marketing to infertility specialists, IVF-focused chain hospitals and increased medical representative coverage to grow the market share within the therapeutic area.

Parent organization Indian Private
NSE symbol CORONA
Founded 2004
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Corona Remedies Ltd?

Answer Field

Corona Remedies Ltd share price is for NSE ₹ 1,479.20 & for BSE ₹ 1,486.00 as on Jan 30 2026 03:30 PM.

What is the Market Cap of Corona Remedies Ltd Share?

Answer Field

The market cap of Corona Remedies Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jan 30 2026 03:30 PM.

What is the 52 Week High and Low of Corona Remedies Ltd?

Answer Field

The 52 Week High and Low of Corona Remedies Ltd for NSE is ₹ 1,541.00 and ₹ 1,336.60 and for BSE is ₹ 1,540.90 and ₹ 1,336.95.

What is 1 year return for Corona Remedies Ltd?

Answer Field

The 1 year returns on the stock has been 0.00%.

What is the P/E Ratio of Corona Remedies Ltd Share?

Answer Field

As on Jan 30 2026 03:30 PM the price-to-earnings (PE) ratio for Corona Remedies Ltd share is 60.72.

What is the PB ratio of Corona Remedies Ltd Share?

Answer Field

As on Jan 30 2026 03:30 PM, the price-to-book (PB) ratio for Corona Remedies Ltd share is 99.03.

How to Buy Corona Remedies Ltd Share?

Answer Field

You can trade in Corona Remedies Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Corona Remedies Ltd Share on Bajaj Broking App?

Answer Field

To buy Corona Remedies Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Corona Remedies Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59